Trial Profile
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Stage I/II Unfavourable Hodgkin Lymphoma. A Randomized Phase II LYSA-FIL-EORTC Intergroup Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Bleomycin; Dacarbazine; Doxorubicin; Vinblastine
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms BREACH
- 18 Aug 2022 Status changed from active, no longer recruiting to completed.
- 22 Jul 2022 Results published in the Journal of Clinical Oncology
- 07 Jul 2022 This trial has been completed in Netherlands(End Date: 2 June 2022) according to European Clinical Trials Database record